LRRK2 is one of the most promising drug targets for Parkinson's disease. Though type I
kinase inhibitors of LRRK2 are under clinical trials, alternative strategies like type II inhibitors …

Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common causes of
Parkinson's disease (PD) to date. Dysfunction in LRRK2 enzymatic activities and elevated …

Despite substantial progress, causal variants are identified only for a minority of familial
Parkinson's disease (PD) cases, leaving high-risk pathogenic variants unidentified,. To …

Background Parkinson's disease is a progressive neurodegenerative disorder with
multifactorial causes, among which genetic risk factors play a part. The RAB GTPases are …

The leucine-rich repeat kinase 2 (LRRK2) phosphorylates a subset of RAB GTPases, and
their phosphorylation levels are elevated by Parkinson's disease (PD)-linked mutations of …

Leucine-rich repeat kinase 2 (LRRK2) is the most common gene responsible for familial
Parkinson's disease (PD). The gene product of LRRK2 contains multiple protein domains …

Abstract The Parkinson's Disease (PD)-linked protein Leucine Rich Repeat Kinase 2
(LRRK2) consists of seven domains, including a kinase and a Roc G-domain. Despite the …

Leucine-rich repeat kinase 2 (LRRK2) has been reported to be associated with familial and
idiopathic Parkinson's disease (PD) risk and is a promising target for drug discovery against …

Roco proteins entered the limelight after mutations in human LRRK2 were identified as a
major cause of familial Parkinson's disease. LRRK2 is a large and complex protein …

Leucine-rich repeat protein kinase 2 (LRRK2) is a multi-domain protein encompassing two
of biology's most critical molecular switches, a kinase and a GTPase, and mutations in …